Purdue University School of Pharmacy designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Release - April 30, 2011
Expiration - April 30, 2012
*This program has expired. CME credit is no longer available.
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Education (ACCME) through the joint sponsorship of Purdue University School of Pharmacy and Focus Medical Communications. Purdue University School of Pharmacy, an equal access/equal opportunity institution, is accredited by the ACCME to provide continuing medical education for physicians.
All faculty and staff involved in the planning or presentation of continuing education activities sponsored/provided by Purdue University School of Pharmacy
are required to disclose to the audience any real or apparent commercial financial affiliations related to the content of the presentation or enduring material.
Dr Gish is a Consultant/Speaker bureau for Abbott, Bayer AG, Bristol-Myers Squibb Company, Durect, Hepahope, Hoffmann LaRoche Ltd., Genentech, Gilead Sciences, GlobeImmune, Merck, OSI/Astellas, Pharmasset, Schering-Plough Corporation MERCK, Kadmon, VitalTherapies, GlaxoSmithKline, Onyx, Roche Pharmaceuticals, Three Rivers, Salix, and SciClone Pharmaceuticals. He has received Grants/Research Support from Astellas (OSI), Bayer-Onyx, Bristol-Myers Squibb Company, Genentech/ F. Hoffman-LaRoche Ltd., Gilead Sciences, Genentech, Merck, and Pharmasset. He is a Major Stock Shareholder for Hepahope and a Minor stock Shareholder for Kinex. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity.
The Focus Medical Communications staff and Purdue University School of Pharmacy staff have no relationships to disclose.